PAI-039 - CAS# 393105-53-8 0287 Pretreatment of cancer cells with

Pretreatment of cancer cells with a KDM5-specific inhibitor results in the ablation of a subpopulation of cancer cells that can serve as the founders for therapeutic relapse

It inhibits phosphorylation of the mTORC1 substrates 4E-BP1 and S6K1 as well as the mTORC2 substrate AKT in diverse cancer models in vitro and in vivo

MERcK-5 inhibits IL2 driven proliferation of CTLL cells with IC50=0

Chemical Name: Compound Library of Histone Methyltransferase

InChi: InChI=1S/C21H25N3O4/c1-23-9-11-24(12-10-23)19-8-7-16(21(26)28-3)14-18(19)22-20(25)15-5-4-6-17(13-15)27-2/h4-8

PAI-039 - CAS# 393105-53-8 0287 Pretreatment of cancer cells withPAI 039, CAS No. 393105 53 8, is a novel plasminogen activator inhibitor 1 (PAI 1) inhibitor. The pharmacokinetic profile of PAI 039 indicated an oral bioavailability of 43 + 15. 3% and a plasma half life of 6. 2 + 1. 3 h. PAI 039 is an orally active prothrombolytic drug that inhibits PAI 1 and accelerates fibrinolysis while maintaining normal coagulation in a model of coronary occlusion . PAI 039 exerts antithrombotic efficacy in rat models of